TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 34 filers reported holding TCR2 THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $57,000 | +7.5% | 19,706 | +3.8% | 0.00% | – |
| Q1 2022 | $53,000 | -38.4% | 18,982 | +2.5% | 0.00% | – |
| Q4 2021 | $86,000 | -75.1% | 18,521 | -54.5% | 0.00% | – |
| Q3 2021 | $346,000 | +7.5% | 40,711 | +107.6% | 0.00% | – |
| Q2 2021 | $322,000 | -86.0% | 19,610 | -81.1% | 0.00% | -100.0% |
| Q1 2021 | $2,297,000 | -28.4% | 104,004 | +0.3% | 0.00% | -50.0% |
| Q4 2020 | $3,208,000 | -11.6% | 103,709 | -42.0% | 0.00% | 0.0% |
| Q3 2020 | $3,631,000 | +2900.8% | 178,721 | +2162.9% | 0.00% | – |
| Q2 2020 | $121,000 | +332.1% | 7,898 | +115.3% | 0.00% | – |
| Q1 2020 | $28,000 | -49.1% | 3,668 | -6.0% | 0.00% | – |
| Q4 2019 | $55,000 | +19.6% | 3,902 | +25.8% | 0.00% | – |
| Q3 2019 | $46,000 | +155.6% | 3,101 | +131.4% | 0.00% | – |
| Q2 2019 | $18,000 | – | 1,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $6,076,298 | 2.53% |
| MPM BioImpact LLC | 3,370,982 | $5,056,473 | 1.31% |
| TANG CAPITAL MANAGEMENT LLC | 3,399,745 | $5,099,618 | 0.76% |
| Newtyn Management, LLC | 1,015,920 | $1,523,880 | 0.30% |
| Artal Group S.A. | 750,000 | $1,125 | 0.07% |
| Long Focus Capital Management, LLC | 566,270 | $849,405 | 0.05% |
| Redmile Group, LLC | 658,336 | $987,504 | 0.04% |
| HARBOR CAPITAL ADVISORS, INC. | 67,642 | $101,463 | 0.03% |
| X-Square Capital, LLC | 31,720 | $48 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 71,046 | $106,569 | 0.02% |